
Anavex Life Sciences Corp. AVXL
$ 8.39
-3.34%
Quarterly report 2024-Q4
added 02-12-2025
Country |
![]() |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
CEO |
Dr. Christopher Missling |
Employees in the company |
16 |
Shares |
83.5 M |
Market Cap[1] |
$ 700 M |
EBITDA (LTM) |
$ -51.1 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.